Track And Trace: FDA Seeks Wholesaler Info Beyond Legal Requirements
This article was originally published in The Pink Sheet Daily
FDA wants wholesalers and third-party logistics providers to give disciplinary information even though not required by DQSA; agency then plans to release the data.
You may also be interested in...
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
The FDA commissioner also does not want the agency setting goals for rare disease treatment development.
Expedited approval pathway had been a secondary option when traditional approval was not possible, but the CBER director wants surrogate endpoints increasingly considered from the beginning, especially with pediatric rare disease gene therapies.